The father of the dominant theory of Alzheimer’s disease told another eminent researcher he is “causing harm” by criticizing ...

UW has begun treating patients with donanemab, a new Alzheimer’s medication that may slow cognitive decline in people with ...

“While we don’t know whether donanemab or lecanemab can arrest Alzheimer’s, they do appear to help people with mild cognitive impairment and extend the time they are independent and able to ...

SEATTLE — There's new hope for people in the early stages of Alzheimer's disease. A new medication called donanemab appears ...

The second U.S. drug shown to slow the progression of early Alzheimer's has arrived in Seattle-area clinics. One of the first ...

A team of scientists, including researchers from University College London (UCL), has discovered key differences in how four ...

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the ...

One described the approval of lecanemab as “no panacea” for patients, for example, while another went as far as to suggest that, in their eyes, donanemab offered “no net benefit” at all.

In addition, Eisai must conduct a post-authorization safety study, including setting up a patient registry for the European Union. Now each European country must set its own rules for access and ...

Donanemab works similarly to lecanemab, another promising Alzheimer's drug. Patients on lecanemab need infusions every two weeks, while donanemab is administered once a month. Between his ...

A team of scientists including UCL researchers has tested four anti-amyloid Alzheimer's therapeutics to find out how the ...